Indian Peptide Drugs Market
The Indian peptide drugs market is expected to reach USD 883.0 Million in 2022 from USD 381.8 Million in 2016 and is expected to register a CAGR of 15.0%. Factors such as increasing prevalence of chronic diseases, rising aging population, and increasing healthcare expenditure are contributing to the growth of this market.
Indian Peptide Drugs
Market Dynamics
Drivers
· Rising Incidence of Diseases
· Favorable Government Initiatives for the Pharmaceutical Sector
Restraint
· Availability of Alternative Drugs
Opportunity
· Patent Expiry of Blockbuster Peptides
Challenge
· Regulatory and Pricing Issues
The Indian peptide
drugs market is segmented by type and application.
By type, the Indian peptide drugs market is segmented into hormonal, antifungal, antibiotic, ACE inhibitor and others. Hormonal segment dominated the Indian peptide drugs market in 2016. The growing incidence of diabetes, cancer diseases in India are the key factors driving the growth of this segment.
On the basis of application, the Indian peptide drugs market segmented into diabetes, cancer, cardiovascular disease (CVD), gynecological application, infectious diseases, osteoporosis, and other applications (acromegaly, multiple sclerosis, and hepatitis).
Download a PDF
Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77044734
Key players in the
Indian peptide drugs market
Key players operating in the Indian peptide drugs market include Abbott Laboratories (U.S.), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), and Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India)
Indian Heparin Market
The Indian anticoagulant drugs market is expected to reach USD 170.2 Million by 2022 from USD 127.8 Million in 2016, at a CAGR of 4.9%. The growing incidence of coagulation disorders and government support for pharmaceutical companies are expected to drive the growth of this market.
Indian Heparin Market
Dynamics
Drivers
· Growing Incidence of Coagulation Disorders
· Government Support for the Pharmaceutical Industry
Restraint
· High Degree of Consolidation to Hinder Small Players from Entering the Market
Challenge
· Regulatory and Pricing Issues
The Indian anticoagulant drugs market is segmented by type.
By low molecular weight heparin type, the Indian anticoagulant drugs market is segmented into heparin sodium, enoxaparin sodium, fondaparinux, and dalteparin sodium. The enoxaparin sodium segment dominated the Indian anticoagulant drugs market in 2016. The growing incidence of coagulation disorder in India are the key factors driving the growth of this segment.
Request a Sample
Pages @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77044734
Key players in the
Indian anticoagulant drugs market
Key players operating in the Indian anticoagulant drugs
market include Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla
Ltd. (India), Bharat Serum (India), Pfizer Inc. (US), Abbott Laboratories (US),
and Lupin Ltd. (India), Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals
Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India),
Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent
Pharmaceuticals (India), and Micro Labs Ltd. (India).
Comments
Post a Comment